GPCR Therapeutics Announces Publication in PNAS Using Cutting Edge Spectroscopy to Detect GPCR Heteromers on Live Cancer Cells

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

This research underscores the company’s commitment to targeting diseases with cutting-edge approaches against GPCRs and discovering novel therapeutics.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Monday, April 1, 2024
Information
Tags: 
Technology, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, Data Management, Science, Oncology, Texas Tech University, GPCR, Associate, CXCR4, Adrenaline, PNAS, National academy, G protein-coupled receptor, Drug, Therapy, Pharmaceutical industry
Geotags: 
SOUTH KOREA, UNITED STATES, NORTH AMERICA, ASIA PACIFIC, CALIFORNIA, SEOUL
⚠ partially generated by AI ↴
Organisation: 
GPCR THERAPEUTICS, GPCR THERAPEUTICS, INC.
Summary
Key Points: 
  • This research underscores the company’s commitment to targeting diseases with cutting-edge approaches against GPCRs and discovering novel therapeutics.
  • Detection of multimeric complexes by CXCR4 with other GPCRs in a live-cell environment validates the dual GPCR targeting hypothesis.
  • The work uses time-resolved fluorescence spectroscopy to quantify CXCR4 and β2AR interactions as they form complexes in live cells under physiological conditions.
  • Dr. Dong Seung Seen, Founder and CEO of GPCR Therapeutics based in Seoul, spoke about Dr. Caculitan’s accomplishments.


GPCR Therapeutics, Inc., a clinical-stage, international biopharmaceutical company, is pleased to announce the publication in the esteemed scientific journal, Proceedings of the National Academy of Sciences (PNAS) that was spearheaded by Dr. Niña Caculitan, Director of Clinical Development.

This research underscores the company’s commitment to targeting diseases with cutting-edge approaches against GPCRs and discovering novel therapeutics. Detection of multimeric complexes by CXCR4 with other GPCRs in a live-cell environment validates the dual GPCR targeting hypothesis. The paper, authored in collaboration with Prof. Adam Smith, Associate Professor at Texas Tech University, is titled “The β2-adrenergic receptor associates with CXCR4 multimers in human cancer cells.”

Both CXCR4 and β2AR receptors play active roles in oncogenesis. The work uses time-resolved fluorescence spectroscopy to quantify CXCR4 and β2AR interactions as they form complexes in live cells under physiological conditions. Differential propensities of GPCRs to cluster in non-cancer versus cancer cell lines was observed, suggesting that GPCR multimerization is significantly affected by the plasma membrane environment. Furthermore, the ligand for β2AR, epinephrine, increases the CXCR4-β2AR heteromerization. Thus, antagonizing its binding could decrease heteromerization and may have therapeutic benefits that can be missed by targeting only CXCR4. This supports the development of new drugs to treat CXCR4-positive cancers using combination therapies.

Dr. Dong Seung Seen, Founder and CEO of GPCR Therapeutics based in Seoul, spoke about Dr. Caculitan’s accomplishments. “Dr. Caculitan represents the highest ideals that our entire team strive for. It is this level of understanding complex science that will lead us to success with the unique approach upon which our company was founded.”

References:

(2024). The β2-adrenergic receptor associates with CXCR4 multimers in human cancer cells. Proceedings of the National Academy of Sciences, 121(14), e2304897121.

https://doi.org/10.1073/pnas.2304897121

About GPCR Therapeutics

GPCR Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapeutics built on its proprietary GPCR data. GPCR Therapeutics has its HQ in Seoul and a subsidiary in the San Francisco Bay Area, USA. The company’s lead asset, GPC-100/Burixafor, targets CXCR4. GPCR has a US phase 2 trial of GPC-100, G-CSF and Propranolol, a beta blocker, for stem cell mobilization in multiple myeloma patients (NCT05561751). For more information, please visit gpcr.co.kr and follow us on LinkedIn.

Copyright: 
Copyright Business Wire 2024